Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Ohe
Y
Y
Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.
Sasaki
Y
Y
Shinkai
T
T
Eguchi
K
K
Tamura
T
T
Kojima
A
A
Kunikane
H
H
Okamoto
H
H
Karato
A
A
Ohmatsu
H
H
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D003967:Diarrhea / Q000139:chemically induced; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000077146:Irinotecan; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D010610:Pharyngeal Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin